US Nuclear warns going concern as sales fall, SG&A soars; seeks ~$5M to survive

US Nuclear Corp. (PINK: UCLE) - Q1 2025 snapshot

What's happening inside the company (straight to the point)
- Management reports a material going-concern doubt: net loss for the quarter and an accumulated deficit raise "substantial doubt" about continuing as a going concern. Management plans to raise capital (est. need ≈ $5,000,000 over 12 months).
- Operations show improving gross margins but shrinking top line and sharply higher operating expenses driven by stock‑based compensation for advisors/consultants.
- Significant related‑party activity and debt-to-equity conversions continue to reshape the balance sheet (series A preferred issuance, conversions of convertible notes, shareholder loans).

Key financial statistics (reported)
- Sales: $476,705 (Q1 2025) vs $627,750 (Q1 2024), change $(151,045) or -24.1%
- Cost of sales: $127,788 (Q1 2025) vs $273,981 (Q1 2024)
- Gross profit: $348,917 (Q1 2025) vs $353,769 (Q1 2024)
- Gross margin: 73.19% (Q1 2025) vs 56.36% (Q1 2024) - management attributes this to product mix and material cost fluctuations
- Selling, general & administrative: $872,797 (Q1 2025) vs $498,198 - up $374,599 or 75.2%; stock‑based compensation cited as $451,099 of the increase
- Loss from operations: $(523,880) vs $(144,429)
- Other expense (mostly interest and related): $(36,352) vs $(17,549)
- Net loss: $(560,232) vs $(161,978)
- Net loss attributable to common stockholders: $(631,459) (after preferred dividends of $71,227)
- Loss per share - basic and diluted: $(0.01) (weighted-average shares 57,309,903)
- Cash at quarter end: $68,489 (down from $130,840 at 12/31/2024) - net decrease in cash $(62,351) for the quarter
- Accounts receivable, net: $60,985 (down from $351,398)
- Inventories: $1,750,121 (up from $1,536,014) - raw materials $966,164; WIP $350,928; finished goods $433,029
- Total assets: $2,497,830; Total liabilities: $3,180,350; Total shareholders' equity: $(682,520) (accumulated deficit $(20,307,784))
- Current assets $1,921,511 vs current liabilities $2,374,928 → working capital deficit ≈ $453,417
- Convertible notes payable, net of discount: $144,000 (down from $405,403) - conversions during the quarter (common shares issued for debt) noted
- Line of credit outstanding: $309,773 (of $400,000 available)
- Customer concentration: two customers accounted for 29% and 35% of sales in Q1 2025
- Warrants outstanding: 6,000,000 (weighted avg. exercise $0.07); potential dilution up to additional 5,000,000 from cashless warrants granted Jan 1, 2025

Income statement - positives
- Gross profit remained healthy at $348,917 despite a 24% decline in revenue; gross margin improved materially to 73.19% (product mix and lower cost of goods sold).
- Cost of goods sold fell sharply (Q1 2025: $127,788 vs Q1 2024: $273,981), indicating margin recovery potential when sales recover.
- The company reduced some debt via conversion to equity (conversions reduced convertible note balances), improving near-term cash outflows for interest/principal.

Income statement - negatives
- Revenues down 24.1% year-over-year - Overhoff sales fell $179,524 and account for the majority of the decline.
- SG&A surged 75.2% to $872,797; stock‑based compensation ($451,099) is the major driver - large non-cash expense dilutes profitability and shareholders.
- Net loss widened to $(560,232) (net loss to commonholders $(631,459) after preferred dividends) - EPS impact negative at $(0.01) on 57.3M weighted shares.
- Preferred dividends accrued and paid impact cash and reported loss (preferred dividends this quarter $71,227; accrued cash dividends $58,311 and 1,166,216 common stock dividends at fair value $87,362 remain outstanding).
- High customer concentration (two customers >60% combined) increases revenue risk if contracts lapse.

Other material issues / liquidity & governance
- Management flagged substantial doubt about going concern and plans to seek financing (private debt/equity).
- Cash used in operating activities: $(92,486) for Q1 2025 (vs $(88,570) prior year); financing provided $30,135.
- Shareholder and related‑party transactions significant: CEO and CFO have provided loans; leases and rent for company facilities are with a CEO‑owned entity; related‑party conversions changed capital structure.
- Disclosure controls and procedures: management concluded disclosure controls and procedures were not effective as of March 31, 2025 - governance and reporting risk to monitor.

What to watch next (near term)
- Success and terms of management's capital‑raising efforts (they state need ≈ $5,000,000 for 12 months).
- Revenue trend at Overhoff (largest revenue driver) and whether customer concentration reduces.
- SG&A trajectory - will stock‑based comp remain elevated or normalize?
- Cash runway: current cash $68,489 with negative working capital - potential need for immediate financing.
- Any further debt conversions, preferred share issuances, or large related‑party transactions that further dilute common shareholders.

Bottom line: US Nuclear Corp. (PINK: UCLE) shows improved gross margins but weaker revenue, much higher SG&A (stock‑based comp), a growing working capital gap, negative equity and an explicit going‑concern warning. The story hinges on rapid access to external capital, stabilizing sales (especially at Overhoff), and governance/controls improvements.